SecBot SecBot
Insider Buy ·Filed Aug 18, 2026

ASND

Ascendis Pharma A/S
NEUTRAL
Impact 3/10
Horizonweeks Processed3mo ago SEC0001610717-26-000360
Insider cluster: 1 insiders, $493K total
Actionable Insight • Neutral

The $493K director buy is too small to be a standalone signal. Monitor for larger insider purchases, especially from C-suite executives, or a catalyst event (e.g., FDA decision, pipeline update) that could justify a more material position. The strong analyst consensus already prices in bullish expectations.

DirectionNeutral
Confidencehigh
Horizonweeks

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$259.62
T+0 close · Aug 18, 2026 · via day close
Latest settled
+2.87%
T+60 · $267.07
Vs SPY
+4.42%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Aug 19 $259.62entry
  2. T+1 · 3mo ago −1.85%α −1.01% · $254.81
  3. T+5 · 3mo ago −3.61%α −3.22% · $250.25
  4. T+20 · 2mo ago −7.93%α −5.98% · $239.04
  5. T+60 · 5d ago +2.87%α +4.42% · $267.07

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Director Jean Jacques Bienaime purchased $493K of ASND stock in two open-market transactions on August 14, 2026, at ~$246/share. This is a modest conviction buy from a director, representing ~0.003% of the $15.3B market cap, a trivial dollar amount relative to company size. The buy is notable only for its timing alongside strong analyst consensus (96% bullish), but the absolute dollar value is too small to carry a meaningful signal.

Key Financial Metrics

Direction
buying
Total Value
$493.0K
Insiders
1

Key Facts

  • Director Jean Jacques Bienaime bought 2,000 shares total for $493K on August 14, 2026
  • Purchases were at ~$245.85 and ~$246.91 per share
  • Total buy represents ~0.003% of ASND's $15.3B market cap
  • Analyst consensus is 96% bullish (25 Buy, 1 Hold, 0 Sell)
  • No C-suite insider participated in this buy

Financial Impact

$493K total insider purchase, negligible relative to $15.3B market cap

insider ownership

Risk Factors

  • Director buy is trivial relative to market cap, may be a routine portfolio adjustment
  • No C-suite participation reduces signal strength

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
96% bullish (26 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 SEC document filed with EDGAR.

DocumentAccession Number
INSIDER-BUY Data (Synthetic)0001610717-26-000360

Track record

41 reports on ASND

Performance horizon

14 of 19 bullish or bearish reports moved the stock their way by T+60. Best: +26.62% at T+20 after the Jun 2, 2026 report. 25 of 27 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $271.96 Now $271.73 −0.08% settles Feb 12
  2. Nov 12, 20264d ago 6-K Neutral 2/10 Entry $275.39 Now $271.73 −1.33% settles Feb 11
  3. Nov 12, 20264d ago 6-K Bullish 6/10 Entry $267.07 Now $271.73 +1.74% settles Feb 10
  4. Nov 12, 20264d ago Press Release Neutral 5/10 Entry $267.07 Now $271.73 +1.74% settles Feb 10
  5. Nov 6, 202610d ago 6-K Bullish 6/10 Entry $259.85 Now $271.73 +4.57% settles Feb 5
  6. Nov 6, 202610d ago Press Release Bullish 6/10 Entry $256.82 Now $271.73 +5.81% settles Feb 4
  7. Nov 5, 202611d ago SC 13G/A Neutral 2/10 Entry $253.45 Now $271.73 +7.21% settles Feb 3
  8. Nov 2, 202614d ago Institutional Cluster Bullish 4/10 Entry $250.17 Now $271.73 +8.62% settles Feb 1
  9. Oct 26, 202621d ago 6-K Bullish 5/10 Entry $245.85 Now $271.73 +10.53% settles Jan 25
  10. Oct 16, 20264w ago 6-K Bullish 7/10 Entry $225.25 Now $271.73 +20.63% settles Jan 13
Showing 10 of 41

US Market Status

Market Closed · Opens Wed (10h 2m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Aug 18, 2026